Ardelyx
ARDX · Nasdaq · United States
Share price · ARDX
Loading chart…
Prices are end-of-day (EOD), delayed by 24 hours · Adjusted for stock splits · Data via Databento
Unusual price moves
Days when ARDX's shares moved far more than they usually do, with what was announced that day or the session before. An announcement on the same day does not show that it caused the move. How the days are picked
- 4 Nov 2026+8.6%
- 7 Aug 2026-17.9%
- 29 Jun 2026-5.8%
Nothing announced by ARDX that day or the session before.
- 26 Jun 2026-8.4%
Nothing announced by ARDX that day or the session before.
- 1 May 2026+8.7%
- 24 Feb 2026+14.1%
Nothing announced by ARDX that day or the session before.
- 20 Feb 2026-15.0%
- 20 Jan 2026+15.0%
Nothing announced by ARDX that day or the session before.
- 9 Jan 2026+10.6%
- 8 Jan 2026+20.1%
Share of unusual movement by asset
For each asset, the share of ARDX's own-move activity since 2 Jul 2024 that fell on the session of one of the asset's own announcements or the session after it. Large moves count for much more than small ones. A session shared by several assets is split between them. A share is shown once an asset has at least 8 event days; below that, its events are listed instead.
Assets
(2 total)
| Target & Modality | |||
|---|---|---|---|
| Approved | NHE3 (sodium/hydrogen exchanger isoform 3)Small molecule | Irritable Bowel Syndrome Irritable Bowel Syndrome with Constipation | |
| Approved | NHE3 (sodium/hydrogen exchanger isoform 3)Small molecule | Chronic Kidney DiseaseHyperphosphatemia |
Upcoming events
(2 total)
Estimated primary-completion dates from ClinicalTrials.gov and expected earnings reports. These are registry estimates, never confirmed readout dates; they can move as trials progress.
Add these trial readouts to your calendar: Apple or Outlook · Google Calendar · .ics link. The calendar updates when a registry date moves.
Financial reports
Quarterly & interim (16)
| Period | Revenue | R&D | Cash & equiv. | Net loss / qtr | Filing |
|---|---|---|---|---|---|
| 2026-Q3 | $128M | $25M | $46M+ $239M short-term inv. | $0.7M$2.2M operating cash flow | report ↗ |
View 15 more
| Period | Revenue | R&D | Cash & equiv. | Net loss / qtr | Filing |
|---|---|---|---|---|---|
| 2026-Q2 | $121M | $26M | $97M+ $185M short-term inv. | $17M-$6.4M operating cash flow | report ↗ |
| 2026-Q1 | $94M | $20M | $31M+ $207M short-term inv. | $38M-$32M operating cash flow | report ↗ |
| 2025-Q3 | $110M | $18M | $43M+ $200M short-term inv. | $1.0M$0.4M operating cash flow | report ↗ |
| 2025-Q2 | $98M | $16M | $90M+ $148M short-term inv. | $19M-$25M operating cash flow | report ↗ |
| 2025-Q1 | $74M | $15M | $31M+ $183M short-term inv. | $41M-$38M operating cash flow | report ↗ |
| 2024-Q3 | $98M | $15M | $47M+ $143M short-term inv. | $0.8M$0.5M operating cash flow | report ↗ |
| 2024-Q2 | $73M | $13M | $42M+ $144M short-term inv. | $16M-$19M operating cash flow | report ↗ |
| 2024-Q1 | $46M | $11M | $36M+ $166M short-term inv. | $27M-$36M operating cash flow | report ↗ |
| 2023-Q3 | $56M | $8.6M | $34M+ $131M short-term inv. | —-$21M operating cash flow | report ↗ |
| 2023-Q2 | $22M | $8.3M | $30M+ $98M short-term inv. | $17M-$15M operating cash flow | report ↗ |
| 2023-Q1 | $11M | $9.1M | $92M+ $38M short-term inv. | $27M-$45M operating cash flow | report ↗ |
| 2022-Q3 | $5.0M | $7.5M | $62M+ $29M short-term inv. | $23M-$25M operating cash flow | report ↗ |
| 2022-Q2 | $2.5M | $9.7M | $53M+ $28M short-term inv. | $27M-$31M operating cash flow | report ↗ |
| 2022-Q1 | $0.5M | $8.8M | $47M+ $43M short-term inv. | $28M-$28M operating cash flow | report ↗ |
| 2021-Q3 | $1.2M | $24M | $75M+ $66M short-term inv. | $44M-$35M operating cash flow | report ↗ |
Annual history (5 years)
| Period | Revenue | R&D | Cash & equiv. | Net loss / qtr | Filing |
|---|---|---|---|---|---|
| 2025-FY | $407M | $72M | $68M+ $197M short-term inv. | $15M-$42M operating cash flow | report ↗ |
Ardelyx reported fiscal 2025 revenue of $407.32M, up 22.1% YoY, with R&D spend of $71.53M, up 36.7% YoY. Cash and equivalents were $68M, and the company reported a net loss of $61.6M, with a quarterly net burn of $61.6M.
During the year, Ardelyx submitted an IND for tenapanor in chronic idiopathic constipation (CIC) and, in January 2026, initiated the Phase 3 ACCEL trial (ten-03-301), with topline data expected in the second half of 2027. The company also announced a development program for RDX10531, a next-generation NHE3 inhibitor, with an IND submission planned for the second half of 2026. In February 2025, Fosun Pharma received NMPA approval for tenapanor for hyperphosphatemia in hemodialysis patients in China. XPHOZAH’s inclusion in the ESRD PPS on January 1, 2025 negatively and materially impacted XPHOZAH revenue in 2025. Ardelyx drew an additional $50M under its term loan facility in Q2 2025, leaving $200M drawn and outstanding at year-end, and established a $100M at-the-market facility under which no shares had been sold as of December 31, 2025.
View 4 more years
| Period | Revenue | R&D | Cash & equiv. | Net loss / qtr | Filing |
|---|---|---|---|---|---|
| 2024-FY | $334M | $52M | $65M+ $185M short-term inv. | $9.8M-$45M operating cash flow | report ↗ |
| 2023-FY | $124M | $36M | $21M+ $163M short-term inv. | $17M-$90M operating cash flow | report ↗ |
| 2022-FY | $52M | $35M | $96M+ $28M short-term inv. | $17M-$70M operating cash flow | report ↗ |
| 2021-FY | $10M | $91M | $72M+ $44M short-term inv. | $40M-$153M operating cash flow | report ↗ |
Insider transactions
Open-market activity, trailing 12 months: 1 purchase ($1.9M), 78 sales ($4.3M). Awards, option exercises and tax-withholding rows are listed below but excluded from these totals.
| Source | ||||||
|---|---|---|---|---|---|---|
| 2026-08-21 | RAAB MICHAEL · director, President & CEO | Open-market sale | 15,009 | $3.86 | $58K | Form 4 |
| 2026-08-21 | Williams Laura A · Chief Patient Officer | Open-market sale | 3,486 | $3.86 | $13K | Form 4 |
| 2026-08-21 | Kelliher Mike · Chief Business Officer | Open-market sale | 3,104 | $3.86 | $12K | Form 4 |
| 2026-08-21 | Foster Eric Duane · Chief Commercial Officer | Open-market sale | 2,598 | $3.86 | $10K | Form 4 |
| 2026-08-21 | Brady James Parker · Chief Human Resources Officer | Open-market sale | 1,976 | $3.86 | $8K | Form 4 |
| 2026-08-21 | Bishop John E · See Remarks | Open-market sale | 17,281 | $3.86 | $67K | Form 4 |
| 2026-08-21 | Reilly Joseph James · See Remarks | Open-market sale | 2,872 | $3.86 | $11K | Form 4 |
| 2026-08-21 | Hohenleitner Susan · Chief Financial Officer | Open-market sale | 1,558 | $3.86 | $6K | Form 4 |
Institutional holders
From SEC Form 13F filings for the quarter ended 2026-03-31 (filed up to 45 days later). 236 reporting institutions held 169.4M shares ($999.9M, 67.4% of shares outstanding).
| # | Institution | Shares | Value |
|---|---|---|---|
| 1 | BlackRock, Inc. | 21,164,132 | $126.8M |
| 2 | MILLENNIUM MANAGEMENT LLC | 17,842,370 | $106.9M |
| 3 | STATE STREET CORP | 13,604,307 | $81.5M |
| 4 | VANGUARD CAPITAL MANAGEMENT LLC | 10,365,512 | $62.1M |
| 5 | JANUS HENDERSON GROUP PLC | 8,371,234 | $50.1M |
| 6 | NOMURA ASSET MANAGEMENT INTERNATIONAL INC. | 8,169,369 | $48.9M |
| 7 | VANGUARD PORTFOLIO MANAGEMENT LLC | 6,661,693 | $39.9M |
| 8 | GEODE CAPITAL MANAGEMENT, LLC | 6,007,455 | $36.0M |
| 9 | Nuveen, LLC | 5,234,683 | $31.4M |
| 10 | TWO SIGMA INVESTMENTS, LP | 4,274,043 | $25.6M |
| 11 | CITADEL ADVISORS LLC | 3,464,774 | $20.8M |
| 12 | GOLDMAN SACHS GROUP INC | 3,216,210 | $19.3M |
| 13 | J. Goldman & Co LP | 3,000,513 | $18.0M |
| 14 | Point72 Asset Management, L.P. | 2,984,261 | $17.9M |
| 15 | AQR CAPITAL MANAGEMENT LLC | 2,439,450 | $14.6M |